Results 271 to 280 of about 13,000,271 (286)

Marstacimab (Hympavzi) for Hemophilia A and B

The Medical Letter on Drugs and Therapeutics
Marstacimab-hncq (Hympavzi – Pfizer), a tissue factor pathway inhibitor (TFPI) antagonist, has been approved by the FDA for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients ≥12 years old who have hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors.
openaire   +2 more sources

Hemophilia B

2019
Surbhi Saini, Amy L. Dunn
openaire   +1 more source

Gene Therapy of Hemophilia B

Thrombosis and Haemostasis, 1993
Kotoku Kurachi, Shou-Nan Yao
openaire   +3 more sources

Hemophilia A and B

2013
Craig M. Kessler, Patrick F. Fogarty
openaire   +2 more sources

The Molecular Genetics of Hemophilia B

Transfusion Medicine Reviews, 1987
Ross T. A. MacGillivray, Valerie A. Geddes   +1 more
openaire   +3 more sources

Investigations on Hemophilia A and B Carriers

2015
Inga Marie Nilsson, O Ramgren, Margareta Blombäck   +2 more
openaire   +3 more sources

Treatment of Hemophilia A and B

2015
openaire   +3 more sources

Hemophilia A and B

2007
Lisa N. Boggio, Craig M. Kessler
openaire   +2 more sources

Understanding the Hemophilias... A, B, and C

The American Journal of Nursing, 1962
openaire   +3 more sources

Carriers of Hemophilia A and Hemophilia B

2018
openaire   +2 more sources